(Abst.) Predicting clinical progression in RRMS patients retrospectively using a myelin content proxy on: June 25, 2026, 09:01:30 pm #1 From PubMed (June 25, 2026)--"Predicting clinical progression in patients with relapsing remitting multiple sclerosis retrospectively using a myelin content proxy": Predicting clinical progression in patients with relapsing remitting multiple sclerosis retrospectively using a myelin content proxy - PubMed By assessing short-term myelin changes outside lesions, using readily available clinical MRI scans, long-term clinical progression in patients with RRMS may be predicted. PubMed · pubmed.ncbi.nlm.nih.gov This small study involved patients taking natalizumab.According to AI, "A myelin content proxy is an indirect measurement used in neuroimaging to estimate the amount of myelin—the protective, fatty sheath insulating nerve fibers. Because directly measuring myelin requires time-consuming, specialized equipment, researchers rely on these "proxies" using standard, readily available brain scans." Last Edit: June 25, 2026, 09:03:11 pm by agate Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
